PDF(961 KB)
PDF(961 KB)
PDF(961 KB)
促性腺激素释放激素激动剂治疗与骨量丢失
Gonadotropin-releasing hormone agonist treatment and bone loss
促性腺激素释放激素激动剂（GnRH-a）已广泛应用于妇科子宫内膜异位症、子宫肌瘤、性早熟等雌激素依赖性疾病的治疗。但其导致的低雌激素血症与骨丢失也愈来愈引起人们的认识和重视。GnRH-a与HRT反向添加疗法可以降低骨丢失、改善生活质量，从而延长GnRH-a治疗时间。
Abstract:Gonadotropin-releasing hormone agonist (GnRHa) has been widely used in the treatment of the endometriosis,uterine myoma and precocious puberty.However long-term GnRHa treatment can induce a hypoestrogenic state and loss of bone mineral density. GnRHa and add-back therapy with HRT can reduce bone mass loss,improve quality of life and prolong GnRHa treatment duration.
促性腺激素释放激素激动剂 / 骨丢失 / 反向添加疗法 / 激素补充治疗
[1］ Lindsay PC,Shaw RW,Coelingh HJ. The effect of add-back tretment with tibolone (livial)on patients treated with the gonadotropin-releasing hormone aginist triptorelin (Decapeptyl)[J].Fertil Steril,1996，65：342-348.
[2］ Dawood MY. Hormonal therapies for endometriosis: implications for bone metabolism[J].Acta Obstet Gynecol Scand Suppl,1994,159：22-34.
[3］ Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis[J].Am J Obstet Gynecol,1992,166：740-745.
[4］ Surrey ES,Voigt B,Fournet I. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add back” therapy[J]. Fertil Steril, 1995,63：747-755.
[5］ Surrey ES.Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached?Add-Back Consensus Working Group[J]. Fertil Steril,1999,71：420-424.
[6］ Zupi E,Marcini D,Sbracia M,et al. Add-back therapy in the treatment of endometriosis-associated pain［J］. Fertil Steril,2004,82(3):1303-1308.
[7］ Laufer MR.Current approaches to optimizing the the treatment of endometriosis in adolescents［J］.Gynecol Obstet Invest,2008,66(suppl 1):19-27.
[8］ 王懿琴，张绍芬,陈珣,等.GnRHa联合经皮雌激素及口服醋酸甲羟孕酮治疗子宫内膜异位症的疗效及安全性分析[J]. 中华妇产科杂志，2009，44（7）:504-508.
[9］ 龙琦琦，张绍芬，韩懿,等.GnRHa与戊酸雌二醇及地屈孕酮反加治疗子宫内膜异位症的临床疗效与安全性[J].中华妇产科杂志，2010,45(4):247-251.
[10］ Yi Han,Shi-En Zou,Shao-Fen Zhang,et al. The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with estrogen-progestogen add-back therapy in endometriosis patients of reproductive age[J]. Int J Clin Exp Med,2013,6(7):583-588.
[11］ Shien Zou,Qiqi Long,Shaofen Zhang,et al. Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women[J]. Int J Clin Exp Med,2013,6(1):67-73.
[12］ Hornstein MD,Yuzpe AA,Burry KA,et al．Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain[J]．Fertil Steril，1995，63(5)：955-962.
[13］ 中华医学会妇产科分会内异症协作组.子宫内膜异位症的诊断与治疗规范[J].中华妇产科杂志,2007,42（9）:645-648.
[14］ Tahara M,Matsuoka T,Yokoi T,et al. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy) [J]. Fertil Steril,2000,73：799-804.
/
| 〈 |
|
〉 |
